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EXPRESSION OF IMMUNE INHIBITORY RECEPTOR ILT3 IN
ACUTE MYELOID LEUKEMIA WITH MONOCYTIC
DIFFERENTIATION
To date, the diagnosis of acute myeloid leukemia
(AML) with monocytic differentiation was limited by the
lack of highly sensitive and specific monocytic markers
(1). Over the last 2 decades, several immunophenotypic
markers (lysozyme, elastase, UPA-R, GM-CSF-R, among
others) were found to be preferentially expressed by
cells belonging to the monocytic lineage, but unfortu-
nately none of them allowed the easy recognition of the
pure M5 FAB subvariety of AML (1–5). It is a great pleas-
ure to recall to our readers the pioneering studies per-
formed by Prof Knapp, and later on by the EGIL group,
aimed at identifying reliable and reproducible reagents
for the detection of granulomonocyte-associated lysoso-
mal protein expression during in vitro and in vivo differ-
entiation of CD34þ hematopoietic progenitor cells along
the myelomonocytic lineages, as well as for the charac-
terization of AML subtypes (1,5). Furthermore, the
methodologies used for the cytofluorimetric analysis of
intracellular antigens have been the object of investiga-
tion by several investigators, with the main aim to
improve the reproducibility and comparability of results
in multicenter trials (6,7). The main unsolved issue still
on the table in this area of investigation continues to be
the absence of a reliable test that reliably identifies the
monocytic lineage of a malignant transformation; to date
neither morphology, cytochemistry, cytogenetics nor mo-
lecular biology have satisfactorily achieved this goal. In
this issue, the study by Dobrowolska et al. (8) has investi-
gated by flow cytometry the expression of immunoglob-
ulin-like transcript 3 (ILT3) in AML patients and has
shown that this new phenotypic marker is expressed in
all cases of AML displaying monocytic differentiation but
not in AML M1/M2 and M3 subtypes. Based on these
findings, ILT3 can be regarded as a highly sensitive and
specific marker that distinguishes AML with monocytic
differentiation from other types of AML. ILT3 is an
immune inhibitory receptor expressed by myelomono-
cytic cells and at high levels by tolerogenic dendritic
cells, making it feasible to be incorporated into the initial
diagnostic work-up and monitoring of patients with
AML. However, the diagnostic usefulness of this pheno-
typic marker for the recognition of the monocytic variant
of AML needs to be validated in larger series of patients.
INABILITY OF A MONOCLONAL ANTI-LIGHT CHAIN
ANTIBODY TO DETECT CLONAL PLASMA CELLS IN
MULTIPLE MYELOMA PATIENTS
There is accumulating evidence in the literature indicat-
ing that multicolor flow cytometry is increasingly impor-
tant for the diagnosis of minimal residual disease (MRD)
assessment of patients with multiple myeloma (MM),
although only sporadic reports have proposed consensus
techniques for their detection (9–12). However, the litera-
ture contains discrepancies in results regarding the exact
immunophenotype of normal and neoplastic plasma cells
(PCs) and their associated clinical significance. These con-
troversies could be due to methodological problems, such
as different gating strategies, the use of different monoclo-
nal antibody clones, different fluorochromes, and the use
of different multiparametric staining procedures. It is also
important to appreciate that flow cytometry can be an
imperfect technique to obtain quantitative information in
evaluating PCs in bone marrow because of the frequent
physical loss of these cells and/or hemodilution with pe-
ripheral blood. To study PC, it is necessary to distinguish
between the normal and neoplastic PC immunopheno-
type. Several studies have reported on the immunopheno-
type of PCs in MGUS and MM and have examined the
immunophenotype of polyclonal PCs (12), thus providing
insights regarding the discrimination between normal ver-
sus clonal PC. Recent reports have also showed that the
immunophenotype of MM PCs can change over time and
that normal PCs are heterogeneous in the expression of
several immunophenotypic markers such as CD19 and
CD56. This implies that for the sensitive, reliable detec-
tion of MRD clonality assessment by the detection of cyto-
plasmic kappa and lambda light chains is advisable (10).
In this regard, the data published in this issue of Cytome-
try by van Velzen et al. (13) provide evidence that the use
of polyclonal over monoclonal antibodies is preferred for
the detection of intracellular immunoglobulin light chains,
thus indicating that the recognition of the monoclonal na-
ture of a given cell proliferation may be a difficult task in
selected cases of MM and/or related disorders.
FLOW CYTOMETRIC TESTING OF IMMUNOLOGICAL
MARKERS FOR GATING MONOCYTES IN PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare
disease clinically characterized by intravascular hemoly-
sis, bone marrow failure, and the high tendency to
thrombosis (14). It is caused by a mutation in the phos-
phatidyl inositol glycan—class A gene leading to partial
or complete loss of the cell membrane molecule called
glycosyl phosphatidyl inositol (GPI) (15,16). Flow
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cytometry is the recognized standard method for the
detection of GPI-deficient clones in PNH and related dis-
orders. Although the International Clinical Cytometry So-
ciety and the International PNH Interest Group have
published guidelines for PNH assays (14), data analysis
has not been standardized. The majority of current ana-
lytical methods use manual gating to enumerate PNH
cells (14–19) although new automated analysis techni-
ques that improve the objectivity of operator input have
also been recently developed (19). Gating strategies
imply the recognition of the various cell types (mono-
cytes, neutrophil granulocytes, and red blood cells)
based on the expression of various phenotypic markers.
In this issue, the paper by Dalal et al. (20) demonstrated
that CD64-based gating showed more distinct clustering
of monocytes than CD33-based gating, allowing for
an improved and more objective gating strategy. Interest-
ingly, the number of monocytes in total as well as
GPI-deficient monocytes derived from both gating strat-
egies was found to be comparable, thus emphasizing the
usefulness of this flow cytometry protocol.
USE OF ANTI-HBF ANTIBODY FOR THE DETECTION AND
QUANTIFICATION OF FETOMATERNAL HEMORRHAGE
The Kleihauer-Betke test (KBT) is the most widely
used assay for fetomaternal hemorrhage (FMH) detection
in rhesus D negative women (21,22). In this issue of
Clinical Cytometry, Pastoret et al. (23) evaluated the
performance of flow cytometry for detecting the occur-
rence of FMH through the use of an anti-HbF antibody
(FMH QuikQuant kit). This assay permits the accurate
quantification of both fetal and adult erythrocytes with
an increased amount of HbF. Based on these findings, it
can be postulated that the accurate quantification of fe-
tal cells could be performed in a number of hematologi-
cal disorders including hemoglobin diseases, hereditary
persistence of HbF, and myelodysplastic syndromes. It is
finally proposed that the FMH QuikQuant kit is a reli-
able and highly reproductive flow cytometric method
for FMH quantification.
COMPARATIVE STUDY OF GIARDIA DIAGNOSTIC METHODS
IN HUMAN FECAL SAMPLES
Over the last decades, several methods were tried for
Giardia detection in stool (24–26). The main aim of
this study was to compare the results between standard
light microscopy, direct immunofluorescence assay
(DIF), and flow cytometry for the detection of Giardia
cyst in human stool samples. From this analysis, El-
Nahas et al. (27) concluded that a direct microscopic
examination is reliable in Giardia diagnosis as a first
choice test. However, DIF proved to be an excellent
technique in clinically suspected cases after negative
microscopy. Interestingly, although the flow cytometry
method was found to be less sensitive to obtain accu-
rate organism’s count, it appeared to be an effective al-
ternative method for the detection of Giardia cysts,
especially for large-scale epidemiological studies or
extensive surveillance programs as it has the beneficial
attribute of speed and does not depend on an experi-
enced microscope viewer.
FLOW CYTOMETRY ASSESSMENT OF REGULATORY T CELL
SUBSETS IN HIV-1 INFECTED SUBJECTS
Regulatory T cells (Tregs) (also known as suppressor
T cells) are a specialized subpopulation of T cells that
act to suppress immune responses, thereby maintaining
homeostasis and self-tolerance. Over the last few years,
evidence from both human and animal models has accu-
mulated indicating that Tregs may play a critical role in
the pathogenesis of several diseases, suggesting that
Tregs may be manipulated toward achieving a desired
therapeutic effect (28). Several reports provided evi-
dence that autologous stem cell transplantation for auto-
immune diseases may induce immunologic self-tolerance
by reprogramming autoreactive T cells, thus restoring
the immune regulatory network. Impairment of Treg de-
velopment and/or function can precipitate a variety of
autoimmune diseases, whereas a higher frequency of
Tregs can render the immune system hyporesponsive to
pathogens (29,30).
In a recent paper, Grant et al. (31) validated a flow
cytometry protocol for the enumeration of FOX-P3
Tregs in clinical samples and saw a signifcant increase
in FoxP3 expression in the patients with type 1 diabe-
tes but not in individuals with multiple sclerosis.
Because FoxP3 has arisen as the prototypic marker to
measure Tregs, along with use of CD127 marker, numer-
ous antibodies have become commercially available.
Another subject, which still needs to be addressed in
future investigations, is represented by the definition of
the immunophenotypic profile of Tregs (29–32). In fact,
in addition to CD4, CD25, and Fox-P3 antigens, several
other antigenic markers such as CD127, CD45 RA,
CD28, CD 152, CD184, and so on have been found to
be expressed by different subpopulations of Tregs, sug-
gesting further characterization of these cell types is
necessary for a better understanding of the functional
role played by the various Tregs cell subsets. Further-
more, instead of intracellular FOXP3 staining, the
CD4þCD25þCD127-phenotype has been proposed as
an alternative approach to identify Tregs in clinical sam-
ples. However, its use remains controversial in viremic
patients. In the article by Saison et al. (33), the
objective of the study was to assess the correlation
between frequencies of CD4þCD25þCD127 and CD4þ
CD25þFOXP3þ lymphocytes in viremic and matched
aviremic HIV-infected patients. From this report, the
authors concluded that the CD4þCD25þCD127 phe-
notype is a satisfactory and easy-to-perform strategy
for the identification of FOXP3þ regulatory T cells in
both viremic and aviremic HIV-1 infected subjects.
Thus, it represents a useful tool for monitoring Tregs
in clinical research studies based on large cohorts of
patients prospectively monitored, including HIV-
infected subjects.
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QUANTIFICATION OF MITOCHONDRIAL TOXICITY IN HIV-
INFECTED INDIVIDUALS BY QUANTITATIVE PCR COMPARED
TO FLOW CYTOMETRY
A great number of cellular and immunological abnor-
malities have been described in HIV-infected individuals
(30,34). Progress in the development of methodologies
to assess antigen-specific T cells as well as mitochondrial
dysfunction has allowed for both qualitative and quanti-
tative damages recognition on HIV-infected cells. Inter-
estingly, the exposure to anti-retroviral treatment was
found associated with a diffuse spectrum of metabolic
adverse reactions consistent with mitochondrial toxicity.
Several studies indicated that dysfunctional HIV spe-
cific cytotoxic T-lymphocytes and mitochondrial altera-
tion exist during disease progression. In this issue,
Wagner et al. (35) compared the ratio of mitochondrial
to nuclear DNA determined by quantitative PCR to the
ratio of mitochondrial to nuclear-encoded proteins by
flow cytometry, in peripheral blood mononuclear cells
from HIV-infected individuals. This experimental work
gave further evidence that a flow cytometry-based proto-
col may provide reliable results in assessing mitochon-
drial toxicity in this disease category.
INTER-LABORATORY ASSESSMENT OF FLOW CYTOMETRIC
MONOCYTE HLA-DR EXPRESSION IN CLINICAL SAMPLES
There is accumulating evidence that a diminished
expression of human leukocyte antigen-DR on circulat-
ing monocytes (mHLA-DR) measured by flow cytometry
is considered a reliable indicator of immunosuppression
in critically ill patients (36,37). It is also known that
monocytes with low HLA-DR expression are known to
be unable to mount a proinflammatory response to any
subsequent bacterial challenge or to properly present
antigens to T cells (37). HLA-DR expression on mono-
cytes has been shown to be predictive of both adverse
outcome and septic complications after trauma, surgery,
pancreatitis, burn, and septic shock. The objective of
the work published in this issue by Demaret et al. (38)
was to test, in an interlaboratory clinical study, a stand-
ardized protocol for mHLA-DR measurement by flow
cytometry. These authors showed the robustness of this
standardized flow cytometric protocol for mHLA-DR
measurement in multicentric clinical studies, thus pro-
viding compelling evidence about the role played by
flow cytometry in these clinical settings.
Francesco Lanza*
Hematology Service, and Stem Cell Transplantation
Clinical and Laboratory Unit
University Hospital—Cremona, Italy
LITERATURE CITED
1. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A,
van’t Veer MB. Proposals for the immunological classification of
acute leukemias. European Group for the Immunological Character-
ization of Leukemias (EGIL). Leukemia 1995;9:1783–1786.
2. Lanza F, Castoldi GL, Castagnari B, Todd RT III, Moretti S, Spisani S,
Latorraca A, Bardi A, Traniello S. Expression and functional role of
urokinase-type plasminogen activator receptor (UPA-R) in normal
and acute leukemic cells. Br J Haematol 1998;103:110–123.
3. Bellos F, Alpermann T, Gouberman E, Haferlach C, Schnittger S,
Haferlach T, Kern W. Evaluation of flow cytometric assessment of
myeloid nuclear differentiation antigen expression as a diagnostic
marker for myelodysplastic syndromes in a series of 269 patients.
Cytometry B Clin Cytom 2012;82B:295–304.
4. Larsen A, Roug A, Just T, Brown G, and Hokland P. Expression of
the hMICL in acute myeloid leukemia—A highly reliable disease
marker at diagnosis and during follow-up. Cytometry B Clin Cytom
2012;82:3–8.
5. Knapp W, Strobl H, Majdic O. Flow cytometric analysis of cell-sur-
face and intracellular antigens in leukemia diagnosis. Cytometry
1994;18:187–198.
6. Lanza F, Moretti S, Latorraca A, Ferrari L, Castagnari B, Castoldi GL.
Cytofluorimetric measurement of cytoplasmic myeloperoxidase by
permeabilisation of blood cells with the FACS lysing solution.
Cytometry 1996;24:292–295.
7. Lanza F, Latorraca A, Moretti S, Castagnari B, Ferrari L, Castoldi GL.
Comparative analysis of different permeabilization methods for the
flow cytometry measurement of cytoplasmic MPO and lysozyme in
normal and leukemic cells. Cytometry 1997;30:1–11
8. Dobrowolska H, Gill KZ, Serban G, Ivan E, Li Q, Qiao W, Suciu-Foca
N, Savage D, Alobeid B, Bhagat G, Colovai AI. Expression of
immune inhibitory receptor ILT3 in acute myeloid leukemia with
monocytic differentiation. Cytometry B Clin Cytom 2013;84B:21–
29.
9. Frebet E, Abraham J, Genevieve F, Lepelley P, Daliphard S, Bardet V,
Amsellem S, Guy J,Mullier F, Durrieu F, Venon M-D, Leleu X, Jaccard
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